US Stock News
Qualcomm Ponders (NASDAQ: QCOM) Intel Design Acquisition
Amidst the fiercely competitive battleground for leadership in the artificial intelligence PC chip market, Qualcomm (NASDAQ: QCOM)
Lilly Invests $1.8 Billion in Irish Manufacturing
Eli Lilly and Company (NYSE: LLY), a global leader in pharmaceuticals, has announced a substantial expansion of its manufacturing operations in Ireland. With a combined investment of $1.8 billion into two major sites, the com
Sprouts Farmers Market (SFM) Coverage Initiated At Sector Perform by RBC Capital
Sprouts Farmers Market (NASDAQ: SFM), the fresh, natural, and organic food retailer, has been initiated with a Sector Perform rating by RBC Capital analyst Steven Shemesh, alongside a price target of $107. With the stock havi
Palantir Rated Neutral At Citi As Stock Looks To Target 52 Week Highs
Palantir Technologies (NYSE: PLTR) stock price has continued to show a significant uptick, increasing by 0.4% in the pre-market to reach a current price of $34.99. With the stock looking to break through $35, and push out abo
Petco’s Stock Price (NASDAQ:WOOF) Makes Big Green YTD Move on Earnings Beat
Petco's stock (NASDAQ: WOOF) added an impressive 32.9% following the release of their second-quarter financial results, indicating a positive investor reaction to the company's earnings report. The notable increase in the pet
Mizuho Remains Optimistic on Alkermes Amidst Competitive Narcolepsy Market
Shares of Alkermes plc (NASDAQ: ALKS) have seen a slight decline today, down 0.78% to $26.78, amidst market reactions to new data from competing biopharmaceutical company, Centessa (NASDAQ: CNTA). The drop reflects investor c
What Can We Expect When Palantir Join’s S&P 500?
Palantir Technologies (NYSE: PLTR), the data analytics company known for its work with government agencies, is poised to join the ranks of the S&P 500 on September 23.
Citi Boost Oracle’s Price Target to $157 (NYSE: ORCL)
Oracle Corporation (NYSE: ORCL) has recently seen a notable increase in its stock price target by analysts at Citi. The financial institution raised its target from $140 to $157, still maintaining an "Neutral" rating on the s
Q32 Bio’s Stock (NASDAQ:QTTB) Hits 52 Week High As Wells Fargo Initiates With Lofty Price Target
With Q32 Bio's stock (NASDAQ: QTTB) experiencing a rise of 4.13% to set a new 52 week high price of $47.96, the market is responding warmly to Wells Fargo's recent initiation of coverage. This bullish perspective arrives part
DraftKings Stock (NASDAQ: DKNG) Down PreMarket Despite Macquarie Optimism
DraftKings stock price (NASDAQ: DKNG) had gained solidly in yesterday's session, adding 1.38%, before making an about turn in this morning's pre-market. With DKNG currently in the red to the tune of 1.94%, the stock is hoveri
AWS Commits £8B for UK Data Center Expansion
Amazon Web Services, the cloud computing arm of Amazon (NASDAQ: AMZN), has announced a substantial investment plan to pump £8 billion into the United Kingdom over t
ExlService (EXLS) Gains Analyst Upgrade Coming Off Recent Highs
ExlService stock (NASDAQ: EXLS) has received a boost in confidence from Jefferies Financial Group, as the firm upgraded its rating from a 'hold' to a 'buy'. With EXLS stoc
GE Aerospace (NYSE: GE) Gains Outperform Rating and $201 Target
General Electric Company's (NYSE: GE) aerospace division saw its shares climb 2.56% to $165.35, reflecting a positive assessment from Bernstein analyst Douglas Harned. The analyst initiated coverage of GE Aerospace with an Ou
Relay Therapeutics Price Target Raised to $17 After Strong Day For The Stock (RLAY)
Barclays analyst Peter Lawson has issued a revised price target on Relay Therapeutics stock (NASDAQ: RLAY), raising it from $14 to $17, while maintaining an Overweight rating on the shares. This comes on an impressive day for
Nvidia Faces Rising Competition in AI Chip Market
Nvidia Corporation (NASDAQ:NVDA), a leading manufacturer of graphics processing units (GPUs), has long been at the forefront of the
Summit Therapeutics Stock Price Hits New Highs, Analysts Like It
Summit Therapeutics stock (NASDAQ: SMMT) hit a new high of $21.50, as results from a recent trial set off a wave of analyst price target upgrades that helped push bullish sentiment to new levels. The firm received a significa
Nio Continues To Accelerate (NYSE: NIO) – Growth In Sales, With Stock Price Following
Nio Inc (NYSE: NIO), a leading Chinese electric vehicle (EV) manufacturer, has been on plenty of watchlists in recent days with the stock price adding another 10.96% in trading to begin the week. This price jump brings the cu
Google’s EU Fine Upheld
In a landmark judgment, the European Union's top court has upheld a significant fine against tech giant Alphabet's Google. The fine amounts to 2.42 billion euros (
What To Expect From Oracle’s Earnings After Market Close?
Oracle's stock price (NYSE: ORCL) has gained 8% in the lead up to today's after market earnings report, and with the stock fast closing in on 52 week highs today (+0.99%), we take a look at what markets are expecting.
Travere Therapeutics (TVTX) Gains New Buy Rating, With $25 Price Target
Travere Therapeutics stock (NASDAQ: TVTX) ended last week with a surge of 10.57% to reach $10.98, and have continued in the pre-market today, up an additional 4.37% at $11.46 after Guggenheim upgraded the
Boeing Avoids Strike with Union Agreement – Stock Climbing Off 52 Week Lows
In a significant development for the aerospace industry, Boeing (NYSE: BA) has successfully forged a tentative agreement with its union, thus averting a potentially costly strike. This move promises to inject a dose of stabil
Fox Corp (NASDAQ: FOXA) Downgraded To Neutral
Shares of Fox Corporation (NASDAQ: FOXA) experienced a marginal downtick during the trading day, with a percentage change of -0.15% in the pre-market, leaving the stock price at $40.25. Despite this slight movement, a notable
Eli Lilly’s Strategic Price Cut to Boost Weight Loss Drug Market Presence
Eli Lilly share price (NYSE: LLY) is trading up 0.75% in the pre-market session as the global pharmaceutical company continues to capture significant attention for its robust portfolio of therapies that cater to various medic